Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

OncoTargets and Therapy

Volumn 7, Issue , 2013, Pages 13-21

  Verstovsek, Srdan ^a   Quintas Cardama, Alfonso ^a   Kantarjian, Hagop M ^a   Gotlib, Jason ^b   Gupta, Vikas ^c   Atallah, Ehab ^d   Mascarenhas, John ^e   Sun, William ^f   Sarlis, Nicholas J ^f   Sandor, Victor ^f   Levy, Richard S ^f   Mesa, Ruben A ^g  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f Experimental Station   (United States)

^g MAYO CLINIC   (United States)

Author keywords

COMFORT I; Dose titration; JAK2 inhibitor; Myelofibrosis; Ruxolitinib; Treatment related cytopenias

Indexed keywords

HEMOGLOBIN; PLACEBO; RUXOLITINIB;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANEMIA; ARTICLE; BONE PAIN; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOPENIA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EARLY SATIETY; FATIGUE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MYALGIA; MYELOFIBROSIS; NEUTROPENIA; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN UNDER LEFT RIB; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SPLEEN SIZE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84890462687     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S53348     Document Type: Article

References (18)

1. Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP. MPN-associated myelofibrosis (MPN-MF). Leuk Res. 2011;35(1):12-13.
2. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
3. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc. 2012; 87(1):25-33.
4. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
5. Gregory SA, Mesa RA, Hoffman R, Shammo JM. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol. 2011;9(9 Suppl 22):1-16.
6. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009;60:233-245.
7. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res. 2007;31(6):737-740.
8. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19(26): 4399-4413.
9. Incyte Corporation. Jakafi [prescribing information]. 2013. Available from: http://www.incyte.com/sites/default/files/Jakafi_PI.pdf. Accessed September 24, 2013.
10. Canadian Newswire. Jakavi the first medication to receive Health Canada approval to treat patients with myelofibrosis [press release]. Dorval, QC: CNW. July 5, 2012. Available from: http://www.newswire.ca/en/story/1003655/-pr-jakavi-the-first-medication-to-receive-health-canada-approval-to-treat-patients-with-myelofibrosis. Accessed July 9, 2013
11. Novartis. Novartis drug Jakavi first medication to receive European Commission approval to treat patients with myelofibrosis [press release]. Basel, Switzerland: Novartis; August 28, 2012. Available from: http://www.novartis.com/newsroom/media-releases/en/2012/1636508.shtml. Accessed July 9, 2013.
12. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807.
13. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
14. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. Epub Sept 13, 2013.
15. Cervantes F, Kiladjian JJ, Niederwieser D, et al. Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) [abstract]. Blood. 2012;120(21):801.
16. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood. 2000;95(1):19-29.
17. Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31(10):1285-1292.
18. Talpaz M, Paquette R, Afrin L, et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 × 109/L): A comparison to patients with normal or high starting platelet count [abstract]. Blood. 2012;120(21):176.